🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Thrilled to announce our Annual Meeting Featured Voices! Get ready for a wealth of expert perspectives and engaging discussions throughout the meeting. Don't miss out – follow along and contribute to the conversation using the official hashtag: #ASCO25

GU Research Digest for the week of May 10 - 16: a selection of publications about GU cancers in high-impact journals. Search the PMIDs on pubmed.ncbi.nlm.nih.gov to read!

👶 Bringing your little ones to #ASCO25? Don’t worry — ASCO has you covered! There’s a dedicated feeding room and even a kids’ area. Free onsite childcare is available at McCormick Place (first-come, first-served), and child registration is offered for those under 19

The #ASCO25 annual meeting will be held this week from 5/30 to 6/3! The attached schedules show highlights of Cedars-Sinai and Cedars-Sinai Cancer clinicians and researchers. ASCO (4 of 5)

Heading to #ASCO25? Join us May 31, 6–8 p.m., for the CU Cancer Center ASCO Reception at the Tower Lounge, InterContinental Hotel, Chicago Magnificent Mile. Unwind, connect & celebrate the future of cancer care. We can't wait to see you there!

Love that Conquer Cancer, the ASCO Foundation managed to capture in the video below this simply magical moment when Alexis LeVee, MD won her ASCO YIA! It has been a joy to co-mentor this superstar in #breastcancer w Heather McArthur, MD, MPH UTSW Simmons Cancer Center (Heather, TY! As a #kidneycancer doc I was way out of my

Congrats to Cristiane D Bergerot - a Kure It sponsored researcher!

So proud of you Fumiko Ladd Chino, MD, FASCO! It has been a pleasure working with you over this past year. You, Mina S. Sedrak, Namrata (Neena) Vijayvergia MD & I.DagogoJackMD rocked the stage today - and did a brilliant job representing the ASCO LDP class! Thanks for giving us all such an invigorating start to

Join City of Hope and Marcel van den Brink for an evening of connection and conversation during #ASCO25! Submit your R.S.V.P. to [email protected].

With all the amazing presentations at #ASCO25, just wanted to take a moment to share some of our data related to #biomarkers from the #IMmotion010 phase III study, a trial of adjuvant #atezolizumab vs pbo. A tremendous team helped me put this together, including Wenxin (Vincent) Xu

this phase III trial. As a reminder, the study included pts with locazlied high-risk #kidneycancer. The study failed to meet its primary endpoint, as we published in The Lancet. However, there was a huge investment in correlative studies - prior clinical data & our correlative

At #ASCO24, Laurence Albiges @gustaveroussy presented data pertaining to #KIM1, showing that high serum #KIM1 was associated with improved outcome with #atezolizumab, demonstrating for the 1st time a viable adjuvant predictive biomarker for IO in #kidneycancer. At #ASCO25, we presented

... for the first time, tissue data in an adjuvant study of IO for #kidneycancer. Robert Motzer MD Brian Rini, MD et al have previously published data in Cancer Cell data that established 7 "subtypes" of #kidneycancer, with varying IO sensitivity. We assessed these subtypes in our study,

So what is the different in subtype between #KIM1 high & low? You can see in the plot below some key differences - #angiogenesis pathways more prominent in #KIM1 low, #immune pathways more prominent in #KIM1 high. You can see some key differences between pts w long & short DFS on

In my opinion, the most valuable resource in this translational study were paired tissues collected at baseline & recurrence. At a #DNA level you can see stability across most alterations (e.g., #VHL) but some evolution in genes such as #CDKN2A, #mTOR pathway genes & so on. (6/9)

The distribution of gene signatures was also of interest. Shown on the left you can see pooled data across arms, but spend some time looking at the #Sankey plots on the second image. Fascinating to see the wide range of evolutionary patterns from baseline to recurrence in pts

In evaluating signatures, some impt observations. One key finding was downregulation of #MHC1 signature in pts receiving #atezolizumab. A putative mechanism of resistance to #PDL1 based therapies - welcome to insights on how this can be countered. (8/9)

In conclusion, a massive effort for which credit first & foremost goes to the pts & families who participated in the study. I must also give credit to the study sponsor - as #McDermott highlighted in his eloquent discussion at #ASCO25, #biomarker studies are a necessary element

#ASCO25: City of Hope’s Sumanta K. Pal, MD, FASCO breaks down IMmotion010 — a phase 3 #clinicaltrial aiming to uncover the mechanisms behind therapy resistance in patients with localized #kidneycancer.

From H.I.Albert Einstein to City of Hope — postdoctoral fellow Miguel Zugman shares his journey to City of Hope and working alongside Sumanta K. Pal, MD, FASCO. In this video, he also gives a quick recap of the data he presented at #ASCO25.